117 related articles for article (PubMed ID: 17982495)
1. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation.
Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Takasugi K; Iseki T; Tojo A; Asano S
Bone Marrow Transplant; 2008 Feb; 41(4):371-6. PubMed ID: 17982495
[TBL] [Abstract][Full Text] [Related]
2. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Narimatsu H; Kami M; Kato D; Matsumura T; Murashige N; Kusumi E; Yuji K; Hori A; Shibata T; Masuoka K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S
Transpl Infect Dis; 2007 Mar; 9(1):11-5. PubMed ID: 17313465
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
Takami A; Mochizuki K; Ito S; Sugimori C; Yamashita T; Asakura H; Okumura H; Nakao S
Transplant Proc; 2007; 39(1):237-9. PubMed ID: 17275512
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation.
Tomonari A; Iseki T; Takahashi S; Ooi J; Yamada T; Takasugi K; Nagamura F; Uchimaru K; Tojo A; Asano S
Ann Hematol; 2004 Sep; 83(9):573-7. PubMed ID: 15221283
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
6. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation.
Vij R; Khoury H; Brown R; Goodnough LT; Devine SM; Blum W; Adkins D; DiPersio JF
Bone Marrow Transplant; 2003 Oct; 32(7):703-7. PubMed ID: 13130318
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
[TBL] [Abstract][Full Text] [Related]
8. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
9. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
10. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
11. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
12. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
[TBL] [Abstract][Full Text] [Related]
14. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
J Clin Microbiol; 2011 Dec; 49(12):4179-84. PubMed ID: 22031700
[TBL] [Abstract][Full Text] [Related]
16. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
[TBL] [Abstract][Full Text] [Related]
17. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y
Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
[TBL] [Abstract][Full Text] [Related]
20. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G
Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]